Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B

Royalty Pharma plc

2024-FY EPS reported $1.91 revenue$2,263,576,000

Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).
Net cash from operations $743M in Q4, $2,769M for FY. Adjusted EBITDA $669M (Q4), $2,565M (FY).
2025 Portfolio Receipts guidance $2,900M–$3,050M (+4–9% growth), excluding future transactions.
Capital deployed $2.8B in 2024; new $3B share repurchase program authorized in Jan 2025, $2B planned in 2025.
Acquisition of external manager RP Management for ~$1.1B in equity/cash/debt; expected Q2 2025 close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.